FreeTheAI

Johnson & Johnson Shares Drop Despite Beating Earnings Estimates as Medical Device Sales Fall Short

BearishHigh impact
JNJ$248.61 −5.73%

Johnson & Johnson (NYSE:JNJ) saw its shares slide more than 5% on Tuesday, heading toward their largest single-day loss in over eighteen months. Although the healthcare giant posted better-than-expected earnings and raised its overall financial guidance for the full year, a revenue miss in its medical device segment weighed heavily on investor sentiment.

The weakness stemmed from the company's MedTech division, which reported $8.64 billion in sales—representing a 2.5% increase year over year, but missing Wall Street predictions of $8.71 billion. The decline in Johnson & Johnson stock also dragged on broader healthcare funds, including the State Street Health Care Select Sector SPDR ETF (NYSE:XLV), where the firm sits as the second-largest holding.

Looking ahead, management emphasized that core operational fundamentals in the medical technology division remain solid. However, investors will be keeping a close eye on future profitability, as recent acquisitions of Firefly Bio and Sail Biomedicines are expected to reduce 2027 adjusted earnings per share by a combined $1.36.

Key points

  • Johnson & Johnson (NYSE:JNJ) beat quarterly profit expectations and raised its full-year outlook.
  • Shares fell over 5% following a revenue shortfall in the company's MedTech division.
  • MedTech sales reached $8.64 billion, missing the $8.71 billion expected by analysts.
  • Deals for Firefly Bio and Sail Biomedicines will reduce 2027 adjusted profit by $1.36 per share.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why is Johnson & Johnson stock dropping today?

Johnson & Johnson stock fell because sales in its MedTech medical device unit came in at $8.64 billion, missing analyst expectations of $8.71 billion, despite the company beating profit targets and raising full-year forecasts.

Did Johnson & Johnson beat quarterly earnings expectations?

Yes, Johnson & Johnson beat overall profit estimates and raised its full-year guidance, though weakness in medical device revenue outweighed the positive results.

How will recent deals impact J&J's future earnings?

Management disclosed that recent agreements for Firefly Bio and Sail Biomedicines will cut adjusted earnings by a combined $1.36 per share in 2027.